according to the inquiry, the enterprise type of Shandong Buchang Pharmaceutical Co., Ltd. belongs to joint stock limited company (invested by Hong Kong, Macao and Taiwan, listed). Shandong Buchang Pharmaceutical Co., Ltd. (referred to as Buchang Pharmaceutical) was established in 21 and completed the shareholding system reform in 212. In July 216, it passed the IPO audit of the China Securities Regulatory Commission and was successfully listed on November 18, 216. During the 17-year development, Buchang Pharmaceutical has built a clear development strategy, "focusing on serious diseases and cultivating large varieties". With patented Chinese patent medicines as the core, the company is committed to the modernization of Chinese medicine, giving full play to the important role of Chinese medicine in the field of cardiovascular and cerebrovascular diseases, and forming a three-dimensional product pattern based on the cardiovascular and cerebrovascular market, covering the traditional advantages of Chinese patent medicines, focusing on serious diseases and cultivating large varieties. Based on the theory of treating brain and heart at the same time, Buchang Pharmaceutical has developed and cultivated three exclusive patented varieties, namely Naoxintong Capsule, Wenxin Granule and Danhong Injection, which cover common cardiovascular and cerebrovascular diseases such as stroke, arrhythmia, insufficient blood supply and ischemic infarction.